Why the ‘Halloween Indicator’ isn’t working — and what smart investors are doing instead
Followers of ‘sell in May and go away’ have lost out on a stock rally
Followers of ‘sell in May and go away’ have lost out on a stock rally
With U.S. Treasury yields on the rise, financial planners say they’re seeing a growing interest in bonds, especially among investors looking to secure fixed income in retirement.
President Donald Trump is spending time this week talking up big job-creating projects in battleground states.
Tanker stocks have been on fire this year. Here's why their momentum can stand
New research says the problem is worse than we thought.
Wall Street just got a health check on the U.S. economy — and almost all the news was positive.
Every investor knows the drill: When markets buckle, buy gold. But in September, that playbook hasn’t worked as expected.
A critical bottleneck in data centers is creating a massive runway for networking stocks like Celestica, according to Bernstein.
A “retirement policy statement” lays out instructions that you can stick to.
There has been a rise in entrepreneurship among young Americans as the entry-level labor market has become tougher to join.
The S&P 500 has gained slightly in September, but three-quarters of its components have declined.
Behind on your 2026 savings goal? The right budgeting app and high-yield savings account can help you get back on track.
Look at a bull put spread to bet on continued upside toward our $615 target while keeping the risk limited.
The Senate will vote on bills that would ban members from trading stocks while in office, and to address data center-related utility costs, amid Democratic opposition.
With AI spending consuming the cash of the market's richest companies, balance sheet metrics led by free cash flow are getting more investing attention.
Stellantis CEO Antonio Filosa on Wednesday reconfirmed the company's 2026 guidance and its plans to be cash-flow positive by 2027.
Some well-meaning career advice from parents is "totally useless" for new grads today, according to journalist Jodi Kantor.
The company is working on an experimental amylin drug to see if it can help people lose weight and manage their diabetes — much like a GLP-1.
While investors worry a spike in global bond yields will drag U.S. equities into correction territory, strategists at BofA Global Research say the real threat lies elsewhere.
Unusual trading patterns on Kalshi and Polymarket are drawing scrutiny as experts debate whether reported volumes reflect organic market activity.